Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Antioxid Redox Signal ; 39(7-9): 591-619, 2023 09.
Article de Anglais | MEDLINE | ID: mdl-37470214

RÉSUMÉ

Significance: Mitochondria are subcellular organelles performing essential metabolic functions contributing to cellular bioenergetics and regulation of cell growth or death. The basic mitochondrial function in fulfilling the need for cell growth and vitality is evidenced whereby cancer cells with depleted mitochondrial DNA (rho zero, p0 cells) no longer form tumors until newly recruited mitochondria are internalized into the rho zero cells. Herein lies the absolute dependency on mitochondria for tumor growth. Hence, mitochondria are key regulators of cell death (by apoptosis, necroptosis, or other forms of cell death) and are, therefore, important targets for anticancer therapy. Recent Advances: Mitochondrial plasticity regulating their state of fusion or fission is key to the chemoresistance properties of cancer cells by promoting pro-survival pathways, enabling the mitochondria to mitigate against the cellular stresses and extreme conditions within the tumor microenvironment caused by chemotherapy, hypoxia, or oxidative stress. Critical Issues: This review discusses many characteristics of mitochondria, the processes and pathways controlling the dynamic changes occurring in the morphology of mitochondria, the roles of reactive oxygen species, and their relationship with mitochondrial fission or fusion. It also examines the relationship of redox to mitophagy when mitochondria become compromised and its effect on cancer cell survival, stemness, and the changes accompanying malignant progression from primary tumors to metastatic disease. Future Directions: A challenging question that arises is whether the changes in mitochondrial dynamics and their regulation can provide opportunities for improving drug targeting during cancer treatment and enhancing survival outcomes. Antioxid. Redox Signal. 39, 591-619.


Sujet(s)
Résistance aux médicaments antinéoplasiques , Tumeurs , Humains , Mitochondries/métabolisme , Tumeurs/métabolisme , ADN mitochondrial/métabolisme , Oxydoréduction , Dynamique mitochondriale , Microenvironnement tumoral
2.
Cell Mol Immunol ; 20(6): 600-612, 2023 06.
Article de Anglais | MEDLINE | ID: mdl-37173422

RÉSUMÉ

Mesenchymal stem cells (MSCs) play diverse roles ranging from regeneration and wound healing to immune signaling. Recent investigations have indicated the crucial role of these multipotent stem cells in regulating various aspects of the immune system. MSCs express unique signaling molecules and secrete various soluble factors that play critical roles in modulating and shaping immune responses, and in some other cases, MSCs can also exert direct antimicrobial effects, thereby helping with the eradication of invading organisms. Recently, it has been demonstrated that MSCs are recruited at the periphery of the granuloma containing Mycobacterium tuberculosis and exert "Janus"-like functions by harboring pathogens and mediating host protective immune responses. This leads to the establishment of a dynamic balance between the host and the pathogen. MSCs function through various immunomodulatory factors such as nitric oxide (NO), IDO, and immunosuppressive cytokines. Recently, our group has shown that M.tb uses MSCs as a niche to evade host protective immune surveillance mechanisms and establish dormancy. MSCs also express a large number of ABC efflux pumps; therefore, dormant M.tb residing in MSCs are exposed to a suboptimal dose of drugs. Therefore, it is highly likely that drug resistance is coupled with dormancy and originates within MSCs. In this review, we discussed various immunomodulatory properties of MSCs, their interactions with important immune cells, and soluble factors. We also discussed the possible roles of MSCs in the outcome of multiple infections and in shaping the immune system, which may provide insight into therapeutic approaches using these cells in different infection models.


Sujet(s)
Maladies transmissibles , Cellules souches mésenchymateuses , Mycobacterium tuberculosis , Tuberculose , Humains , Cytokines , Immunomodulation , Cellules souches mésenchymateuses/physiologie
3.
Life Sci ; 321: 121535, 2023 May 15.
Article de Anglais | MEDLINE | ID: mdl-36906255

RÉSUMÉ

MicroRNAs are critical regulators of the plethora of genes, including FOXO "forkhead" dependent transcription factors, which are bonafide tumour suppressors. The FOXO family members modulate a hub of cellular processes like apoptosis, cell cycle arrest, differentiation, ROS detoxification, and longevity. Aberrant expression of FOXOs in human cancers has been observed due to their down-regulation by diverse microRNAs, which are predominantly involved in tumour initiation, chemo-resistance and tumour progression. Chemo-resistance is a major obstacle in cancer treatment. Over 90% of casualties in cancer patients are reportedly associated with chemo-resistance. Here, we have primarily discussed the structure, functions of FOXO and also their post-translational modifications which influence the activities of these FOXO family members. Further, we have addressed the role of microRNAs in carcinogenesis by regulating the FOXOs at post-transcriptional level. Therefore, microRNAs-FOXO axis can be exploited as a novel cancer therapy. The administration of microRNA-based cancer therapy is likely to be beneficial to curb chemo-resistance in cancers.


Sujet(s)
microARN , Tumeurs , Humains , microARN/génétique , microARN/métabolisme , Tumeurs/traitement médicamenteux , Tumeurs/génétique , Facteurs de transcription Forkhead/génétique , Facteurs de transcription Forkhead/métabolisme , Maturation post-traductionnelle des protéines , Différenciation cellulaire
4.
PLoS Pathog ; 17(8): e1009805, 2021 08.
Article de Anglais | MEDLINE | ID: mdl-34415976

RÉSUMÉ

Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.


Sujet(s)
Antituberculeux/pharmacologie , Lésions hépatiques dues aux substances/prévention et contrôle , Immunothérapie/méthodes , Isoniazide/pharmacologie , Lutéoline/pharmacologie , Mycobacterium tuberculosis/immunologie , Tuberculose/traitement médicamenteux , Animaux , Lésions hépatiques dues aux substances/étiologie , Association de médicaments , Facteurs immunologiques , Isoniazide/effets indésirables , Souris , Souris de lignée C57BL , Mycobacterium tuberculosis/effets des médicaments et des substances chimiques , Tuberculose/immunologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...